Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.
The FDA has lifted the partial clinical hold on the phase 1 trial of NX-2127, a novel BTK inhibitor, for the treatment of patients with relapsed or refractory B-cell malignancies.1
The hold was put in place in November 2023 following communication by Nurix Therapeutics, NX-2127’s creator, to the FDA of its intention to improve manufacturing processes.
“We are pleased with the timely resolution of the partial clinical hold, which allows us to reinitiate enrollment in the NX-2127 Phase 1 study utilizing drug product from our new manufacturing process,” said Paula G. O’Connor, MD, executive vice president and head of clinical development at Nurix, in a press release.
Enrollment in the phase 1 trial will be reinitiated, and patients with aggressive forms of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), who have previously achieved durable responses, will be prioritized. Patients who are currently enrolled in the trial will continue to receive treatment according to the study protocol.
In December 2023, findings from the study of NX-2127 were presented at the American Society of Hematology Annual Meeting. The findings showed that NX-2127 demonstrated dose-dependent pharmacokinetics and a mean half-life of 2 to 4 days among all patient cohorts. Further, rapid BTK degradation was observed.2
“NX-2127 had a manageable safety profile that was consistent with previous reports of BTK-targeted and immunomodulatory therapies and treatment with NX-2127 resulted in encouraging and durable responses in a heavily pretreated patient populations including patients with BTK resistance mutations in both non-Hodgkin lymphoma and in [chronic lymphocytic leukemia (CLL)],” study author, Alexey Danilov, MD, PhD, associate director of the Toni Stephenson Lymphoma Center and Professor in the Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, said in a presentation of the data.
The phase 1a/1b study of NX-2127 has an estimated enrollment of 160 patients with relapsed or refractory B-cell malignancies, including CLL, small lymphocytic lymphoma, MCL, follicular lymphoma, marginal zone lymphoma, primary central nervous system lymphoma (PCNSL), DLBCL, or Waldenstrom macroglobulinemia.3
The study’s primary end points are dose-limiting toxicities, maximum tolerated dose, overall response rate, and incidence of adverse events and laboratory abnormalities. Secondary end points include pharmacokinetics, duration of response, progression-free survival, overall survival, and complete response rate.
To be eligible for study participation, patients must be 18 years of age or older, have an ECOG performance status of 0 or 1 for non-PCNSL indications, an ECOG performance status of 0 to 2 for PCNSL indications, and adequate marrow and organ function. Patients with history of autoimmune disease, toxicities from previous anticancer treatments, or active infection are not eligible to participate.
The study has an anticipated completion date of December 2025.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More